{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:21:56Z","timestamp":1789042916496,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403425"],"award-info":[{"award-number":["82403425"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lenvatinib, a first-line therapy for hepatocellular carcinoma (HCC), is frequently compromised by the development of acquired resistance. Although aberrant protein ubiquitination contributes to drug resistance, the underlying mechanisms remain incompletely understood. In this study, we identify ubiquitin-specific protease 32 (USP32) as a clinically significant oncogene that is overexpressed in HCC and closely associated with aggressive tumor progression and lenvatinib resistance. USP32 knockdown markedly inhibits tumor growth, metastasis, and restores lenvatinib sensitivity both in vitro and in vivo, whereas USP32 overexpression aggravates malignant behaviors. Mechanistically, USP32 directly interacts with and deubiquitinates DEAD-box helicase 17 (DDX17) by cleaving K48-linked polyubiquitin chains, thereby stabilizing DDX17. Furthermore, DDX17 transcriptionally represses the tumor-suppressive microRNA miR-3163, leading to hyperactivation of the MAPK signaling pathway involved in lenvatinib resistance. Notably, combined treatment with the MAPK inhibitor selumetinib and lenvatinib synergistically overcomes drug resistance in lenvatinib-resistant xenograft models. Collectively, our findings identify USP32 as an important regulator of HCC malignancy and lenvatinib resistance via the DDX17\/miR-3163\/MAPK axis, highlighting its potential as a therapeutic target in refractory HCC.<\/jats:p>","DOI":"10.1038\/s41419-026-09040-1","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:24:08Z","timestamp":1782404648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deubiquitinase USP32 stabilizes DDX17 to promote tumor progression and lenvatinib resistance in hepatocellular carcinoma via the miR-3163\/MAPK pathway"],"prefix":"10.1038","volume":"17","author":[{"given":"Yang","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Ran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Wen","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Feng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7108-2520","authenticated-orcid":false,"given":"Shao-Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"9040_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","volume":"164","author":"MR Toh","year":"2023","unstructured":"Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PK, et al. Global Epidemiology and Genetics of Hepatocellular Carcinoma. Gastroenterology. 2023;164:766\u201382.","journal-title":"Gastroenterology"},{"key":"9040_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.suronc.2016.03.002","volume":"25","author":"MS Grandhi","year":"2016","unstructured":"Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74\u201385.","journal-title":"Surg Oncol"},{"key":"9040_CR3","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.2147\/IJN.S193192","volume":"14","author":"L Liu","year":"2019","unstructured":"Liu L, Dai H, Wu Y, Li B, Yi J, Xu C, et al. In vitro and in vivo mechanism of hepatocellular carcinoma inhibition by \u03b2-TCP nanoparticles. Int J Nanomed. 2019;14:3491\u2013502.","journal-title":"Int J Nanomed"},{"key":"9040_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12606-7","volume":"10","author":"L Wei","year":"2019","unstructured":"Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, et al. Genome-wide CRISPR\/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun. 2019;10:4681.","journal-title":"Nat Commun"},{"key":"9040_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"9040_CR6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371.","journal-title":"Int J Cancer"},{"key":"9040_CR7","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459\u201365.","journal-title":"Clin Cancer Res"},{"key":"9040_CR8","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1080\/15548627.2022.2117893","volume":"19","author":"J Pan","year":"2023","unstructured":"Pan J, Zhang M, Dong L, Ji S, Zhang J, Zhang S, et al. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy. 2023;19:1184\u201398.","journal-title":"Autophagy"},{"key":"9040_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3892\/ol.2023.14116","volume":"26","author":"M Takahashi","year":"2023","unstructured":"Takahashi M, Araki T, Yashima H, Nagamine A, Nagano D, Yamamoto K. Increased c\u2011SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma. Oncol Lett. 2023;26:529.","journal-title":"Oncol Lett"},{"key":"9040_CR10","doi-asserted-by":"publisher","first-page":"5754.","DOI":"10.3390\/ijms22115754","volume":"22","author":"T Zou","year":"2021","unstructured":"Zou T, Lin Z. The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression. Int J Mol Sci. 2021;22:5754.","journal-title":"Int J Mol Sci"},{"key":"9040_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41418-020-00648-0","volume":"28","author":"F Dang","year":"2021","unstructured":"Dang F, Nie L, Wei W. Ubiquitin signaling in cell cycle control and tumorigenesis. Cell Death Differ. 2021;28:427\u201338.","journal-title":"Cell Death Differ"},{"key":"9040_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2017.09.040","volume":"171","author":"RG Yau","year":"2017","unstructured":"Yau RG, Doerner K, Castellanos ER, Haakonsen DL, Werner A, Wang N, et al. Assembly and Function of Heterotypic Ubiquitin Chains in Cell-Cycle and Protein Quality Control. Cell. 2017;171:918\u2013.e920.","journal-title":"Cell"},{"key":"9040_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1034\/j.1600-065X.2003.00043.x","volume":"193","author":"JC Lee","year":"2003","unstructured":"Lee JC, Peter ME. Regulation of apoptosis by ubiquitination. Immunol Rev. 2003;193:39\u201347.","journal-title":"Immunol Rev"},{"key":"9040_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06183-3","volume":"14","author":"L Gao","year":"2023","unstructured":"Gao L, Zhang W, Shi XH, Chang X, Han Y, Liu C, et al. The mechanism of linear ubiquitination in regulating cell death and correlative diseases. Cell Death Dis. 2023;14:659.","journal-title":"Cell Death Dis"},{"key":"9040_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1204","volume":"13","author":"C Sampson","year":"2023","unstructured":"Sampson C, Wang Q, Otkur W, Zhao H, Lu Y, Liu X, et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin Transl Med. 2023;13:e1204.","journal-title":"Clin Transl Med"},{"key":"9040_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00528-z","volume":"13","author":"S Li","year":"2024","unstructured":"Li S, Yang L, Ding X, Sun H, Dong X, Yang F, et al. USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway. Oncogenesis. 2024;13:27.","journal-title":"Oncogenesis"},{"key":"9040_CR17","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.7150\/ijbs.43117","volume":"16","author":"N Dou","year":"2020","unstructured":"Dou N, Hu Q, Li L, Wu Q, Li Y, Gao Y. USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2. Int J Biol Sci. 2020;16:1648\u201357.","journal-title":"Int J Biol Sci"},{"key":"9040_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bj.2020.03.001","volume":"43","author":"KJ Wu","year":"2020","unstructured":"Wu KJ. The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness. Biomed J. 2020;43:107\u201314.","journal-title":"Biomed J"},{"key":"9040_CR19","doi-asserted-by":"publisher","first-page":"1.","DOI":"10.1038\/s41419-022-05508-y","volume":"14","author":"G Zhao","year":"2023","unstructured":"Zhao G, Wang Q, Zhang Y, Gu R, Liu M, Li Q. DDX17 induces epithelial-mesenchymal transition and metastasis through the miR-149-3p\/CYBRD1 pathway in colorectal cancer. Cell Death Dis. 2023;14:1.","journal-title":"Cell Death Dis"},{"key":"9040_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/hep.32195","volume":"75","author":"HZ Zhou","year":"2022","unstructured":"Zhou HZ, Li F, Cheng ST, Xu Y, Deng HJ, Gu DY, et al. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis. Hepatology. 2022;75:847\u201365.","journal-title":"Hepatology"},{"key":"9040_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41388-023-02600-1","volume":"42","author":"C Li","year":"2023","unstructured":"Li C, Gao Z, Cui Z, Liu Z, Bian Y, Sun H, et al. Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours. Oncogene. 2023;42:894\u2013910.","journal-title":"Oncogene"},{"key":"9040_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41388-022-02545-x","volume":"42","author":"C Jin","year":"2023","unstructured":"Jin C, Han-Hua D, Qiu-Meng L, Deng N, Peng-Chen D, Jie M, et al. MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma. Oncogene. 2023;42:169\u201383.","journal-title":"Oncogene"},{"key":"9040_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2023-1","volume":"10","author":"B Yang","year":"2019","unstructured":"Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, et al. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis. 2019;10:784.","journal-title":"Cell Death Dis"},{"key":"9040_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1080\/15384047.2020.1738908","volume":"21","author":"C Shi","year":"2020","unstructured":"Shi C, Yang Q, Pan S, Lin X, Xu G, Luo Y, et al. LncRNA OIP5-AS1 promotes cell proliferation and migration and induces angiogenesis via regulating miR-3163\/VEGFA in hepatocellular carcinoma. Cancer Biol Ther. 2020;21:604\u201314.","journal-title":"Cancer Biol Ther"},{"key":"9040_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/eci.12441","volume":"45","author":"B Delire","year":"2015","unstructured":"Delire B, St\u00e4rkel P. The Ras\/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest. 2015;45:609\u201323.","journal-title":"Eur J Clin Invest"},{"key":"9040_CR26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2174\/1568009622666220428111327","volume":"22","author":"J Guo","year":"2022","unstructured":"Guo J, Zhao J, Xu Q, Huang D. Resistance of Lenvatinib in Hepatocellular Carcinoma. Curr Cancer Drug Targets. 2022;22:865\u201378.","journal-title":"Curr Cancer Drug Targets"},{"key":"9040_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273:114\u201327.","journal-title":"J Intern Med"},{"key":"9040_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41418-024-01257-x","volume":"31","author":"B Zhang","year":"2024","unstructured":"Zhang B, Li J, Wang Y, Liu X, Yang X, Liao Z, et al. Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16\/TOP2A axis. Cell Death Differ. 2024;31:309\u201321.","journal-title":"Cell Death Differ"},{"key":"9040_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7150\/ijbs.52517","volume":"17","author":"E Chen","year":"2021","unstructured":"Chen E, Li E, Liu H, Zhou Y, Wen L, Wang J, et al. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy. Int J Biol Sci. 2021;17:781\u201395.","journal-title":"Int J Biol Sci"},{"key":"9040_CR30","doi-asserted-by":"publisher","first-page":"164.","DOI":"10.3892\/mmr.2023.13050","volume":"28","author":"GB Liu","year":"2023","unstructured":"Liu GB, Cheng YX, Li HM, Liu Y, Sun LX, Wu Q, et al. Ghrelin promotes cardiomyocyte differentiation of adipose tissue\u2011derived mesenchymal stem cells by DDX17\u2011mediated regulation of the SFRP4\/Wnt\/\u03b2\u2011catenin axis. Mol Med Rep. 2023;28:164.","journal-title":"Mol Med Rep"},{"key":"9040_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","volume":"10","author":"Y Song","year":"2023","unstructured":"Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. Genes Dis. 2023;10:76\u201388.","journal-title":"Genes Dis"},{"key":"9040_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123\u201354.","journal-title":"Semin Cancer Biol"},{"key":"9040_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13:113.","journal-title":"J Hematol Oncol"},{"key":"9040_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","volume":"75","author":"M Cargnello","year":"2011","unstructured":"Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75:50\u201383.","journal-title":"Microbiol Mol Biol Rev"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09040-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09040-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09040-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:04:29Z","timestamp":1789041869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09040-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9040"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09040-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All experimental procedures were performed in accordance with the relevant guidelines and regulations. Animal experiments were conducted according to the protocols approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (Approval No [2024]059). The collection and use of clinical data and tissue samples complied with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board and Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (Approval No [2024]339). Written informed consent was obtained from each participating patient.","order":2,"name":"Ethics","label":"Ethics declarations","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"789"}}